After Reaching Milestone, Is Aimmune Therapeutics Incorporated (NASDAQ:AIMT)’s Short Interest Revealing Something?

July 26, 2017 - By Vivian Currie

 After Reaching Milestone, Is Aimmune Therapeutics Incorporated (NASDAQ:AIMT)’s Short Interest Revealing Something?

The stock of Aimmune Therapeutics Incorporated (NASDAQ:AIMT) registered an increase of 10.79% in short interest. AIMT’s total short interest was 4.72 million shares in July as published by FINRA. Its up 10.79% from 4.26 million shares, reported previously. With 232,000 shares average volume, it will take short sellers 20 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Incorporated’s float is 17.59%.

The stock decreased 1.59% or $0.35 during the last trading session, reaching $21.65. About shares traded. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 32.49% since July 26, 2016 and is uptrending. It has outperformed by 15.79% the S&P500.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company has market cap of $1.10 billion. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy , is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It currently has negative earnings. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy.

Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics has $44 highest and $35 lowest target. $39.33’s average target is 81.66% above currents $21.65 stock price. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Tuesday, November 17 report. The firm earned “Mkt Outperform” rating on Monday, September 26 by JMP Securities. The firm has “Overweight” rating given on Monday, August 31 by Piper Jaffray. Bank of America initiated it with “Buy” rating and $36 target in Monday, August 31 report. Credit Suisse initiated Aimmune Therapeutics Inc (NASDAQ:AIMT) rating on Monday, August 31. Credit Suisse has “Outperform” rating and $44 target.

More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Businesswire.com which released: “Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health …” on November 04, 2016, also Seekingalpha.com with their article: “Aimmune Therapeutics’ (AIMT) CEO Dr. Stephen Dilly on Q4 2016 Results …” published on March 15, 2017, Businesswire.com published: “Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase …” on July 05, 2017. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Businesswire.com and their article: “Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 …” published on June 20, 2017 as well as Businesswire.com‘s news article titled: “Aimmune Therapeutics to Present at the Bank of America Merrill Lynch …” with publication date: May 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.